SG10201803999UA - Recombinant factor viii formulations - Google Patents

Recombinant factor viii formulations

Info

Publication number
SG10201803999UA
SG10201803999UA SG10201803999UA SG10201803999UA SG10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA
Authority
SG
Singapore
Prior art keywords
factor viii
recombinant factor
formulations
viii formulations
recombinant
Prior art date
Application number
SG10201803999UA
Inventor
De Qian Wang
Xinghang Ma
Nelly Tsvetkova
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SG10201803999UA publication Critical patent/SG10201803999UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RECOMBINANT FACTOR VIII FORMULATIONS Provided are liquid and lyophilized recombinant Factor VIII formulations, including formulations for polymer-conjugated FVIII such as PEGylated Factor VIII. FIGURE 18
SG10201803999UA 2013-03-15 2014-03-11 Recombinant factor viii formulations SG10201803999UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US201361869191P 2013-08-23 2013-08-23

Publications (1)

Publication Number Publication Date
SG10201803999UA true SG10201803999UA (en) 2018-06-28

Family

ID=51580768

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803999UA SG10201803999UA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations
SG11201507618YA SG11201507618YA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201507618YA SG11201507618YA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Country Status (17)

Country Link
US (1) US20160030524A1 (en)
EP (1) EP2970430A4 (en)
JP (1) JP2016518321A (en)
KR (1) KR20150132449A (en)
CN (1) CN105209487A (en)
AU (1) AU2014237111B2 (en)
BR (1) BR112015022730A2 (en)
CA (1) CA2905739A1 (en)
HK (1) HK1213273A1 (en)
MX (1) MX2015012905A (en)
PE (1) PE20160121A1 (en)
RU (1) RU2015144076A (en)
SG (2) SG10201803999UA (en)
TW (1) TW201521761A (en)
UY (1) UY35412A (en)
WO (1) WO2014150477A1 (en)
ZA (1) ZA201507684B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
EP3374387A1 (en) 2015-11-13 2018-09-19 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
TW202039546A (en) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
US20220305089A1 (en) * 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
KR20010101901A (en) * 1999-02-01 2001-11-15 모리 데쯔지 Cathode-ray tube and its production method
CN100553678C (en) * 1999-02-22 2009-10-28 巴克斯特国际有限公司 The factor VIII formulations of new albumin-free
ES2331909T3 (en) * 2001-06-14 2010-01-20 The Scripps Research Institute FACTOR VIII STABILIZED WITH GENETICALLY MODIFIED DISULFIDE LINKS.
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
CN105753968A (en) * 2004-11-12 2016-07-13 拜尔健康护理有限责任公司 Site-directed modification of fviii
BRPI0708832A2 (en) * 2006-03-31 2011-06-14 Baxter Int proteinacean construction
ES2706296T3 (en) * 2008-11-07 2019-03-28 Univ Connecticut Formulations of Factor VIII
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Also Published As

Publication number Publication date
WO2014150477A1 (en) 2014-09-25
CA2905739A1 (en) 2014-09-25
SG11201507618YA (en) 2015-10-29
BR112015022730A2 (en) 2017-10-31
AU2014237111A1 (en) 2015-10-08
KR20150132449A (en) 2015-11-25
TW201521761A (en) 2015-06-16
PE20160121A1 (en) 2016-03-03
AU2014237111B2 (en) 2018-06-21
HK1213273A1 (en) 2016-06-30
EP2970430A4 (en) 2017-01-11
CN105209487A (en) 2015-12-30
RU2015144076A (en) 2017-04-24
UY35412A (en) 2014-10-31
EP2970430A1 (en) 2016-01-20
JP2016518321A (en) 2016-06-23
MX2015012905A (en) 2016-06-16
US20160030524A1 (en) 2016-02-04
ZA201507684B (en) 2017-06-28

Similar Documents

Publication Publication Date Title
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
PH12016500316A1 (en) Improved adenovirus formulations
MX371187B (en) Therapeutic peptides.
MX2021012014A (en) Adeno-associated virus factor viii vectors.
SG10201803042PA (en) Anti-tim-3 antibodies
IL238130B (en) Recombinant modified viruses comprising pr13.5 promoter and uses thereof
PH12015501392A1 (en) Pesticidal compositions and processes related thereto
EP3043820A4 (en) Methods and compositions comprising purified recombinant polypeptides
MX357202B (en) Virus like particle composition.
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
CY1117214T1 (en) COMPOSITION FOR CONTROLLED OVENTION STUDY
EP2981543A4 (en) Novel 4 7 peptide antagonists
PL3666283T3 (en) Factor viii polypeptide formulations
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
MX2015011052A (en) Oral care compositions.
SG10201803999UA (en) Recombinant factor viii formulations
EP3052526A4 (en) Recombinant polypeptides comprising mhc class ii 1 domains
PT2899198T (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use
MX2015011053A (en) Oral care compositions.
AR095431A1 (en) FORMULATIONS OF FVIII RECOMBINANT
Win The Yati (Vol 09 No 104) 2012/11
UA90689U (en) Lactoverm, complex antiparasitic composition
ES2426017A2 (en) Microemulsion comprising collagenase and uses (Machine-translation by Google Translate, not legally binding)
NZ756883A (en) Adeno-associated virus factor viii vectors
HUE039194T2 (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use